PLX reported higher quarterly profit and nine-month sales, and expects 2026 sales to meet or exceed about $78 million to $83 million. Its cash and deposits support PRX–115 work, with no comparable setback reported.
Higher quarterly profit adds to the stronger sales picture. Protalix also has $48.5 million in cash and deposits to keep advancing PRX–115 for uncontrolled gout. The report names no comparable setback.
Follow Protalix BioTherapeutics (PLX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PLX